9 recruiting. 9 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 9 | Recruiting 9 |
Follow KarX-EC: new trials by email Literature Review of KarX-EC trials Research Report on KarX-EC
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study of KarXT + KarX-EC for Treatment of Irritability in Children and Adolescents With Autism KarXT, KarX-EC, KarXT + KarX-EC Matching Placebo - Irritability Associated With Autism Spectrum Disorder | Phase 3 | Recruiting | Bristol-Myers Squibb | 176 | 2026-10-06 | 2026-11-10 |
| A Study of KarXT + KarX-EC for Treatment of Irritability in Children and Adolescents With Autism Spectrum Disorder KarXT, KarX-EC, KarXT + KarX-EC Matching Placebo - Irritability Associated With Autism Spectrum Disorder | Phase 3 | Recruiting | Bristol-Myers Squibb | 176 | 2026-10-06 | 2026-11-10 |
| A Study to Evaluate the Long-term Safety and Tolerability of Xanomeline and Trospium Chloride for the Treatment of Psychiatric Disorders in Children and Adolescents KarXT, KarX-EC - Schizophrenia, Autism-Related Irritability | Phase 3 | Recruiting | Karuna Therapeutics, Inc., a Bristol Myers Squibb company | 400 | 2026-04-07 | 2026-11-06 |
| A Study to Evaluate Safety and Efficacy of KarXT + KarX-EC as a Treatment for Psychosis Associated With Alzheimer's Disease (ADEPT-5) KarXT, KarX-EC, KarXT + KarX-EC Arm Matching Placebo - Alzheimer Disease, Psychosis | Phase 3 | Recruiting | Bristol-Myers Squibb | 325 | 2026-03-25 | 2026-06-30 |
| A Study to Evaluate the Long-term Efficacy and Safety of KarXT + KarX-EC for Agitation in Alzheimer's Disease (ADAGIO-3) KarXT, KarX-EC - Alzheimer Disease, Agitation | Phase 3 | Recruiting | Bristol-Myers Squibb | 650 | 2025-12-02 | 2026-11-12 |
| A Study to Evaluate the Efficacy and Safety of KarXT + KarX-EC for Cognitive Impairment in Alzheimer's Disease (MINDSET 2) KarXT, KarX-EC, Placebo - Alzheimer's Disease | Phase 3 | Recruiting | Bristol-Myers Squibb | 586 | 2025-07-21 | 2026-11-17 |
| A Phase 3 Study to Evaluate the Safety and Efficacy of KarXT + KarX-EC for the Treatment of Agitation Associated With Alzheimer's Disease Xanomeline/Trospium Chloride Capsule, Xanomeline Enteric Capsule, Placebo - Alzheimer's Disease | Phase 3 | Recruiting | Bristol-Myers Squibb | 426 | 2025-07-16 | 2026-11-03 |
| A Study to Evaluate the Efficacy and Safety of KarXT + KarX-EC for Cognitive Impairment in Alzheimer's Disease KarXT, KarX-EC, Placebo - Alzheimer's Disease | Phase 3 | Recruiting | Bristol-Myers Squibb | 586 | 2025-07-14 | 2026-11-17 |
| A Phase 3 Study to Evaluate the Safety and Efficacy of KarXT + KarX-EC for the Treatment of Agitation Associated With Alzheimer's Disease (ADAGIO-1) Xanomeline/Trospium Chloride Capsule, Xanomeline Enteric Capsule, Placebo - Alzheimer Disease | Phase 3 | Recruiting | Bristol-Myers Squibb | 426 | 2025-07-10 | 2026-11-06 |
Alzheimer Disease (6) · Dementia (3) · Autism Spectrum Disorder (2) · Cognitive Dysfunction (2) · Psychomotor Agitation (2) · Autistic Disorder (1) · Psychotic Disorders (1) · Schizophrenia (1)
Bristol-Myers Squibb (8) · Karuna Therapeutics, Inc., a Bristol Myers Squibb company (1)
United States (9) · Canada (6) · France (6) · Japan (6) · Poland (6) · Puerto Rico (6) · Romania (6) · Spain (6) · Argentina (5) · Australia (5) · Germany (5) · India (5) · Brazil (4) · Greece (4) · Hungary (4)
2025 (6)